Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Kurt A Jaeckle, S K Anderson, Erin L Twohy, Jesse G Dixon, Caterina Giannini, Robert Jenkins, Merrill J Egorin, Jann N Sarkaria, Paul D Brown, P J Flynn, John Schwerkoske, Jan C Buckner, Evanthia Galanis

Journal of Neuro-oncology 2019 July

The last author's first name was truncated in the initial online publication. The original article has been corrected.

Full text links

We have located links that may give you full text access.

Show additional links to paperHide additional links to paper

PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app